In the United States, Johnson & Johnson (J&J) has reached a significant settlement agreement, committing to pay $5.5 billion to resolve approximately 69,000 lawsuits alleging that its talc-based baby powder caused ovarian cancer. This decision was announced on a Monday, marking a pivotal moment in a long-standing legal battle that has seen claims against the company multiply over the years. The settlement covers nearly all outstanding talc-related cases in the country, accounting for 99.75 percent of such lawsuits currently in federal and state courts.
The controversy surrounding talc, a soft mineral once widely used in cosmetics and baby products, has intensified as concerns about its potential links to cancer have grown. In 2024, the World Health Organization classified talc as 'probably carcinogenic to humans,' which has further fueled public scrutiny and legal challenges against J&J. Despite the company's assertion that there is no evidence linking talc to cancer, it ceased the sale of talc-based baby powder in the United States in 2020 and globally in 2023, reflecting the mounting pressure and negative publicity.
The legal troubles for J&J began to escalate in 2016 when a jury ordered the company to pay $72 million to the family of a woman who died from ovarian cancer, marking the first major verdict against the company related to talc use. Although this verdict was overturned a year later, it set a precedent that led to a wave of similar lawsuits across the country. Juries in various cases have awarded substantial damages to plaintiffs, contributing to the growing financial burden on the company.
Erik Haas, J&J's litigation head, expressed that the settlement agreement allows the company to 'put this matter behind it.' Lawyers representing the plaintiffs have welcomed the settlement as a positive resolution to a decade-long court battle. However, it is important to note that this settlement does not extend to the United Kingdom, where a significant product liability case is currently underway, involving over 7,000 potential claimants. This case alleges that J&J was aware of the cancer risks associated with its talc products but continued to sell them, a claim that the company denies. The UK case is being adjudicated in the High Court, highlighting the ongoing legal challenges J&J faces internationally.
